University of Kentucky Markey Cancer Center - Cancer Center Support Grant

肯塔基大学马基癌症中心 - 癌症中心支持补助金

基本信息

批准号：
10257468
负责人：
Bernard Mark Evers
金额：
$ 19.05万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-08 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10257468
关键词：
Achievement Address Appalachian Region Area Award Basic Science Behavioral Research Bioinformatics Biometry Cancer Burden Cancer Center Cancer Center Support Grant Cancer Control Cancer Patient Cancer Research Project Catchment Area Cell Separation Cellular biology Centers of Research Excellence Clinical Clinical Research Clinical Trials Clinical Trials Design Collaborations Communities Community Healthcare Community Networks Community Outreach Community Physician Comprehensive Cancer Center County Coupled Data Sources Development Disease Distress Early Diagnosis Ecology Education Education and Outreach Environmental Risk Factor Epigenetic Process Faculty Recruitment Fellowship Flow Cytometry Foundations Funding Genetic Genomic Instability Genomics Health Professional Healthcare Immunotherapy Incidence Individual Informatics Infrastructure Institution Intervention Intervention Studies Intervention Trial Investments Kentucky Malignant Neoplasms Mediator of activation protein Mentors Metabolic Metabolism Methods Minority Minority Graduate Student Mission Molecular Mutation NCI Center for Cancer Research National Cancer Institute Natural Products Obesity Obesity associated cancer Oncology Outcome Oxidation-Reduction Pathology Patients Phenotype Population Population Research Population Sciences Positioning Attribute Prevention Prevention therapy Preventive Program Development Publications Publishing Quality of life Radon Registries Research Research Personnel Resistance Resource Sharing Resources Risk Factors Role SEER Program Science Scientist Screening for cancer Services Signal Transduction Site Strategic Planning Target Populations Therapeutic Training Transcend Translating Translational Research Translations Underserved Population Universities anticancer research authority base bench to bedside biomedical informatics cancer care cancer genomics cancer health disparity cancer prevention cancer research center director cancer site cancer survival cancer therapy career development clinical development clinical translation cohort college community based participatory research cost drug discovery early phase clinical trial genetic epidemiology health assessment health disparity high school higher education improved innovation instrumentation inter-institutional medically underserved meetings member metabolomics mortality multidisciplinary next generation novel anticancer drug outreach personalized diagnostics personalized intervention population health precision medicine precision medicine clinical trials programs prospective recruit repository response screening standard of care synergism targeted treatment treatment response tumor tumor metabolism undergraduate student

项目摘要

PROJECT SUMMARY/ABSTRACT The Markey Cancer Center (MCC) was established more than 35 years ago as a university-based matrix cancer center at the University of Kentucky (UK), Kentucky's flagship institution of higher education. MCC is the only National Cancer Institute (NCI)-designated Cancer Center in Kentucky, a state of 4.4 million that leads the nation for all-site cancer incidence and mortality and serves as the MCC's catchment area. Over $347M in state, institutional, and philanthropic investment since recruitment of MCC Director Dr. B. Mark Evers (CS) in 2009 have supported significant research and resource expansion, enabling substantial new faculty recruitment, program development, renovation of clinical and shared resource space, and new state-of-the art instrumentation, as well as statewide education and community outreach efforts. The 119 MCC members draw from 28 departments in 8 UK colleges, with 28 new faculty recruited since 2013. Cancer-relevant research funding to MCC investigators exceeds $38.7M in total annual costs, an increase of $10.3M since 2012. Over the last 4 years, 9,357 subjects have been accrued to interventional trials. Members have published 851 cancer-focused publications since 2013, reflecting 28% intra-programmatic, 16% inter-programmatic, and 58% inter-institutional collaborations. Research is conducted within 4 MCC Research Programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics; and Genomic Instability, Epigenetics and Metabolism. Five Shared Resource Facilities (SRFs) facilitate cutting-edge research by providing robust infrastructure for specialized expertise and advanced methods: Biospecimen Procurement and Translational Pathology; Biostatistics and Bioinformatics; Cancer Research Informatics; Flow Cytometry and Cell Sorting; and Redox Metabolism. Two new SRFs (Behavioral and Community-Based Research and Oncogenomics) are in development. Significant achievements include: development of an NCI-sponsored early therapeutics program, including an active Molecular Tumor Board and Precision Medicine Center; expansion of the MCC Network from 8 to 24 sites; establishment of a regional Metabolomics Center (U24); award of 2 new cancer-related centers – a Center of Biomedical Research Excellence (COBRE) in Cancer and Metabolism and a Center for Appalachian Research in Environmental Sciences; and expansion of community outreach/education initiatives across the state. MCC research focuses on Kentucky's most serious cancer burdens with emphasis on the “distressed” Appalachian Kentucky region, where cancer incidence and mortality rates surpass those for the entire state. The MCC brings unique basic, clinical, and population research strengths to this mission. These strengths are integral to all MCC programs and collectively provide robust capacity to deliver transformative interventional research to an important underserved priority population, thereby contributing to national efforts to conquer cancer through discovery and clinical translation, cancer prevention, and community outreach.

项目摘要/摘要 Markey Cancer Center（MCC）成立于35年前，如ASA大学的矩阵肯塔基州旗舰高等教育旗舰上的肯塔基大学癌症中心。肯塔基州唯一的国家癌症研究所（NCI）指定的癌症中心，该州为440万个领导全场取消和死亡的国家，是MCC的集水区。 MCC主任B. Mark Evers博士（CS）的州，研究所，研究所和慈善投资罪名 2009年支持了重大的研究和资源扩展，使大量新教师招聘，计划开发，临床和共享资源空间的翻新以及新的最先进仪器以及全州教育和社区外展工作。来自英国8个学院的28个系，自2013年以来招募了28个新教师。与癌症相关的研究向MCC调查人员提供的资金超过3870万美元的总成本，自2012年以来增长了1030万美元。在过去的四年中，有9,357名HABE受到干预试验。自2013年以来，由癌症的出版物反映了28％的程序内部，16％的程序间截图和58％ Inter-Inter-Inter-Inter-Internitute合作。生物学和预防癌症；治疗学和基因组不稳定性，表观遗传学和代谢。通过为专门的实验经验提供强大的基础设施来促进尖端研究和高级研究方法：生物测量的采购和转化病理学；研究信息学和细胞分类；和基于社区的研究和致癌基因学）正在发展。制定由NCI赞助的早期治疗计划，包括主动分子肿瘤板以及 Precision Medicine Center; 代谢组中心（U24）; 癌症和代谢方面的卓越（毛c），以及阿巴拉契亚环境研究的中心科学和扩展社区外展/教育计划在肯塔基州最严重的癌症负担上，重点是“苦恼”的阿巴拉契亚肯塔基州地区在何处取消和死亡率超过了轮胎状态。这些任务的临床和人口研究实力优势是所有MCC计划的组成部分并集体主张强大的能力，将变革性干预研究提供给重要的能力服务不足的生产人群，从而为国家通过发现征服癌症做出了贡献以及清洁的翻译，预防癌症和社区外展。